Atlas Trials

Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS

Clinical trial NCT01700673 · COMPLETED

Trial details

NCT number
NCT01700673
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Acute Myeloid LeukemiaMyelodysplastic Syndrome
Start date
2013-06-01
Primary completion
2020-06-01
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.